As heart failure rates continue to climb, Duke University Health System is advancing treatment with the implantable Barostim device from CVRx. Barostim helps patients with reduced ejection fraction by sending targeted electrical pulses to neck sensors that communicate with the brain, improving regulation of the heart, kidneys, and vascular system.
To explore the device’s impact, Duke and CVRx are co-hosting a free webinar on May 22, 1 p.m. ET. The expert panel includes:
- Dr. Marat Fudim, cardiologist and device clinic director
- Dr. Joanna Kipnes, hospital medicine specialist and utilization management director
- Bonnie Handke, CVRx senior VP of patient access and reimbursement
The session will cover the technology, clinical benefits, and billing considerations. It’s designed for cardiologists, heart failure specialists, administrators, and healthcare leaders seeking to enhance patient outcomes.
Follow MEDWIRE.AI for updates on heart failure treatments and cardiovascular innovation.
